Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESOC 2023 | Considering stroke trial endpoints

Thalia Field, MD, FRCPC, MHSc, University of British Columbia in Vancouver, Canada, discusses the limitations of current clinical trial endpoints in stroke. One limitation of typically used measures is that they are derived from specific populations, limiting generalizability. For example, when determining patient outcomes after a stroke, the initial formula for the utility-weighted modified Rankin Scale was based on a mainly white, elderly male, British population. However, the quality-of-life outcomes in this group may not necessarily align with other cohorts. Furthermore, researchers also must consider the natural history of the disease, for example patients with ischemic stroke, cerebral venous thrombosis, and intracerebral hemorrhage will have functional gains at different timepoints. This interview took place during the European Stroke Organisation Conference (ESOC) in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Thalia Field reports the following disclosures: Bayer Canada – in kind study medication; advisory board honoraria: Roche Canada, AstraZeneca, HLS Therapeutics; expert witness – Canadian medical protective association.